Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section
Research
Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
I-Ching Sam*1, Francis Drobniewski*
, Philip More*, Melanie Kemp*, and Timothy Brown*
, Philip More*, Melanie Kemp*, and Timothy Brown*
Table 6
Results of LiPA in detecting rifampin resistance in clinical specimens in which MTBC was correctly identified and cultured, stratified by history of antituberculous treatment*
| Treatment history | No. positive/no. tested (%) |
||||
|---|---|---|---|---|---|
| Concordance | Sensitivity | Specificity | PPV | NPV | |
| Current or within 3 mo | 46/48 (95.8) | 8/10 (80.0) | 38/38 (100) | 8/8 (100) | 38/40 (95.0) |
| >3 mo ago | 41/42 (97.6) | 7/7 (100) | 34/35 (97.1) | 7/8 (87.5) | 34/34 (100) |
| None stated | 689/691 (99.7) | 23/23 (100) | 666/668 (99.7) | 23/25 (92.0) | 666/666 (100) |
*LiPA, line probe assay; MTBC, Mycobacterium tuberculosis complex; AFB, acid-fast bacilli; PPV, positive predictive value; NPV, negative predictive value.
1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia
Page created: January 06, 2012
Page updated: January 06, 2012
Page reviewed: January 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.